Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature

BackgroundGastric cancer (GC) still represents the third leading cause of cancer-related death worldwide. Peritoneal relapse (PR) is the most frequent metastasis occurring among patients with advanced gastric cancer. Increasingly more evidence have clarified the tumor immune microenvironment (TIME)...

Full description

Bibliographic Details
Main Authors: Chuang Zhang, Danni Li, Ruoxi Yu, Ce Li, Yujia Song, Xi Chen, Yibo Fan, Yunpeng Liu, Xiujuan Qu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Immunology
Subjects:
TME
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.651033/full
id doaj-fee172f4ee214e8680faaef3cd1f0465
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Chuang Zhang
Chuang Zhang
Chuang Zhang
Chuang Zhang
Danni Li
Danni Li
Danni Li
Danni Li
Ruoxi Yu
Ce Li
Ce Li
Ce Li
Ce Li
Yujia Song
Yujia Song
Yujia Song
Yujia Song
Xi Chen
Xi Chen
Xi Chen
Xi Chen
Yibo Fan
Yibo Fan
Yibo Fan
Yibo Fan
Yunpeng Liu
Yunpeng Liu
Yunpeng Liu
Yunpeng Liu
Xiujuan Qu
Xiujuan Qu
Xiujuan Qu
Xiujuan Qu
spellingShingle Chuang Zhang
Chuang Zhang
Chuang Zhang
Chuang Zhang
Danni Li
Danni Li
Danni Li
Danni Li
Ruoxi Yu
Ce Li
Ce Li
Ce Li
Ce Li
Yujia Song
Yujia Song
Yujia Song
Yujia Song
Xi Chen
Xi Chen
Xi Chen
Xi Chen
Yibo Fan
Yibo Fan
Yibo Fan
Yibo Fan
Yunpeng Liu
Yunpeng Liu
Yunpeng Liu
Yunpeng Liu
Xiujuan Qu
Xiujuan Qu
Xiujuan Qu
Xiujuan Qu
Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature
Frontiers in Immunology
gastric cancer
LASSO
peritoneal relapse
TME
immune signature
author_facet Chuang Zhang
Chuang Zhang
Chuang Zhang
Chuang Zhang
Danni Li
Danni Li
Danni Li
Danni Li
Ruoxi Yu
Ce Li
Ce Li
Ce Li
Ce Li
Yujia Song
Yujia Song
Yujia Song
Yujia Song
Xi Chen
Xi Chen
Xi Chen
Xi Chen
Yibo Fan
Yibo Fan
Yibo Fan
Yibo Fan
Yunpeng Liu
Yunpeng Liu
Yunpeng Liu
Yunpeng Liu
Xiujuan Qu
Xiujuan Qu
Xiujuan Qu
Xiujuan Qu
author_sort Chuang Zhang
title Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature
title_short Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature
title_full Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature
title_fullStr Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature
title_full_unstemmed Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature
title_sort immune landscape of gastric carcinoma tumor microenvironment identifies a peritoneal relapse relevant immune signature
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2021-05-01
description BackgroundGastric cancer (GC) still represents the third leading cause of cancer-related death worldwide. Peritoneal relapse (PR) is the most frequent metastasis occurring among patients with advanced gastric cancer. Increasingly more evidence have clarified the tumor immune microenvironment (TIME) may predict survival and have clinical significance in GC. However, tumor-transcriptomics based immune signatures derived from immune profiling have not been established for predicting the peritoneal recurrence of the advanced GC.MethodsIn this study, we depict the immune landscape of GC by using transcriptome profiling and clinical characteristics retrieved from GSE62254 of Gene Expression Omnibus (GEO). Immune cell infiltration score was evaluated via single-sample gene set enrichment (ssGSEA) analysis algorithm. The least absolute shrinkage and selection operator (LASSO) Cox regression algorithm was used to select the valuable immune cells and construct the final model for the prediction of PR. The receiver operating characteristic (ROC) curve and the Kaplan-Meier curve were used to check the accuracy of PRIs. Gene Set Enrichment Analysis (GSEA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were performed to explore the molecular pathways associated with PRIs.ResultsA peritoneal recurrence related immune score (PRIs) with 10 immune cells was constructed. Compared to the low-PRIs group, the high-PRIs group had a greater risk. The upregulation of the focal adhesion signaling was observed in the high-PRIs subtype by GSEA and KEGG. Multivariate analysis found that both in the internal training cohort and the internal validation cohort, PRIs was a stable and independent predictor for PR. A nomogram that integrated clinicopathological features and PRIs to predict peritoneal relapse was constructed. Subgroup analysis indicated that the PRIs could obviously distinguish peritoneal recurrence in different molecular subtypes, pathological stages and Lauren subtypes, in which PRIs of Epithelial-Mesenchymal Transitions (EMT) subtype, III-IV stage and diffuse subtype are higher respectively.ConclusionOverall, we performed a comprehensive evaluation of the immune landscape of GC and constructed a predictive PR model based on the immune cell infiltration. The PRIs represents novel promising feature of predicting peritoneal recurrence of GC and sheds light on the improvement of the personalized management of GC patients after surgery.
topic gastric cancer
LASSO
peritoneal relapse
TME
immune signature
url https://www.frontiersin.org/articles/10.3389/fimmu.2021.651033/full
work_keys_str_mv AT chuangzhang immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT chuangzhang immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT chuangzhang immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT chuangzhang immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT dannili immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT dannili immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT dannili immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT dannili immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT ruoxiyu immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT celi immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT celi immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT celi immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT celi immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT yujiasong immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT yujiasong immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT yujiasong immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT yujiasong immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT xichen immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT xichen immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT xichen immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT xichen immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT yibofan immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT yibofan immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT yibofan immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT yibofan immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT yunpengliu immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT yunpengliu immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT yunpengliu immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT yunpengliu immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT xiujuanqu immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT xiujuanqu immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT xiujuanqu immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
AT xiujuanqu immunelandscapeofgastriccarcinomatumormicroenvironmentidentifiesaperitonealrelapserelevantimmunesignature
_version_ 1721442724751605760
spelling doaj-fee172f4ee214e8680faaef3cd1f04652021-05-13T06:44:09ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-05-011210.3389/fimmu.2021.651033651033Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune SignatureChuang Zhang0Chuang Zhang1Chuang Zhang2Chuang Zhang3Danni Li4Danni Li5Danni Li6Danni Li7Ruoxi Yu8Ce Li9Ce Li10Ce Li11Ce Li12Yujia Song13Yujia Song14Yujia Song15Yujia Song16Xi Chen17Xi Chen18Xi Chen19Xi Chen20Yibo Fan21Yibo Fan22Yibo Fan23Yibo Fan24Yunpeng Liu25Yunpeng Liu26Yunpeng Liu27Yunpeng Liu28Xiujuan Qu29Xiujuan Qu30Xiujuan Qu31Xiujuan Qu32Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, ChinaKey Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, ChinaLiaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, ChinaKey Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, ChinaDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, ChinaKey Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, ChinaLiaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, ChinaKey Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, ChinaDepartment of Radiation Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institution, Shenyang, ChinaDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, ChinaKey Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, ChinaLiaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, ChinaKey Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, ChinaDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, ChinaKey Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, ChinaLiaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, ChinaKey Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, ChinaDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, ChinaKey Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, ChinaLiaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, ChinaKey Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, ChinaDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, ChinaKey Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, ChinaLiaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, ChinaKey Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, ChinaDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, ChinaKey Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, ChinaLiaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, ChinaKey Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, ChinaDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, ChinaKey Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, ChinaLiaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang, ChinaKey Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang, ChinaBackgroundGastric cancer (GC) still represents the third leading cause of cancer-related death worldwide. Peritoneal relapse (PR) is the most frequent metastasis occurring among patients with advanced gastric cancer. Increasingly more evidence have clarified the tumor immune microenvironment (TIME) may predict survival and have clinical significance in GC. However, tumor-transcriptomics based immune signatures derived from immune profiling have not been established for predicting the peritoneal recurrence of the advanced GC.MethodsIn this study, we depict the immune landscape of GC by using transcriptome profiling and clinical characteristics retrieved from GSE62254 of Gene Expression Omnibus (GEO). Immune cell infiltration score was evaluated via single-sample gene set enrichment (ssGSEA) analysis algorithm. The least absolute shrinkage and selection operator (LASSO) Cox regression algorithm was used to select the valuable immune cells and construct the final model for the prediction of PR. The receiver operating characteristic (ROC) curve and the Kaplan-Meier curve were used to check the accuracy of PRIs. Gene Set Enrichment Analysis (GSEA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were performed to explore the molecular pathways associated with PRIs.ResultsA peritoneal recurrence related immune score (PRIs) with 10 immune cells was constructed. Compared to the low-PRIs group, the high-PRIs group had a greater risk. The upregulation of the focal adhesion signaling was observed in the high-PRIs subtype by GSEA and KEGG. Multivariate analysis found that both in the internal training cohort and the internal validation cohort, PRIs was a stable and independent predictor for PR. A nomogram that integrated clinicopathological features and PRIs to predict peritoneal relapse was constructed. Subgroup analysis indicated that the PRIs could obviously distinguish peritoneal recurrence in different molecular subtypes, pathological stages and Lauren subtypes, in which PRIs of Epithelial-Mesenchymal Transitions (EMT) subtype, III-IV stage and diffuse subtype are higher respectively.ConclusionOverall, we performed a comprehensive evaluation of the immune landscape of GC and constructed a predictive PR model based on the immune cell infiltration. The PRIs represents novel promising feature of predicting peritoneal recurrence of GC and sheds light on the improvement of the personalized management of GC patients after surgery.https://www.frontiersin.org/articles/10.3389/fimmu.2021.651033/fullgastric cancerLASSOperitoneal relapseTMEimmune signature